|
Aug 7
|
LSTA Applauds Executive Order Increasing 401 (K) Access to Private Markets Investments
|
|
Aug 7
|
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Jul 31
|
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
|
|
Jul 17
|
Lisata Secures New Composition of Matter Patent for Certepetide
|
|
Jul 17
|
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
|
|
Jul 15
|
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
|
|
Jun 26
|
Lisata Reports Survival, Response Benefits With Certepetide in Pancreatic Cancer Trial
|
|
Jun 26
|
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
|
|
Jun 18
|
Lisata collaborates with GATC Health on drug development
|
|
Jun 17
|
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
|
|
May 9
|
Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ...
|
|
May 8
|
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
|
|
Apr 15
|
Lisata Therapeutics Announces Research License with Catalent
|
|
Feb 20
|
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
|
|
Oct 3
|
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
|
|
Sep 17
|
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
|
|
Jul 24
|
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
|
|
Jun 13
|
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
|
|
Jan 4
|
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
|
|
Nov 28
|
Lisata Therapeutics to Present at NobleCon19 Investor Conference
|